AUROPHARMA2020-07-012020-09-30in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2020-07-012020-09-30in-bse-fin:FourOperatingExpenses01Member AUROPHARMA2020-07-012020-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2020-07-012020-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AUROPHARMA2020-07-012020-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2020-07-012020-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AUROPHARMA2020-07-012020-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AUROPHARMA2020-07-012020-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AUROPHARMA 2020-04-01 2021-03-31 2020-11-02 INR Lakhs Half yearly true Cash Flow Indirect Single segment Pharmaceutical Products 2020-07-01 2020-09-30 Unaudited Consolidated 64834400000.00 537500000.00 65371900000.00 22251700000.00 6746400000.00 -3840900000.00 9119000000.00 157100000.00 2573400000.00 16230100000.00 53236800000.00 12135100000.00 0.00 12135100000.00 4252500000.00 -379200000.00 3873300000.00 0.00 8261800000.00 0.00 0.00 0.00 -205300000.00 8056500000.00 -433200000.00 7623300000.00 8062300000.00 -5800000.00 7629100000.00 -5800000.00 585900000.00 1 13.75 13.75 0.00 0.00 13.75 13.75 NOTES:t t t t t t n1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. n ttttttt n2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on Consolidated financial statements and Ind AS 28 on Investments in Associates and Joint ventures notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended. n ttttttt n3 The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 11 November 2020. The statutory auditors have carried out limited review of the above results for quarter and half year ended 30 September 2020. An unmodified report has been issued by them thereon. n ttttttt n4 Exceptional items for the current period/year represent acquisition related costs. n ttttttt n5 The Group operates in only one segment viz., 'Pharmaceutical Products'. n ttttttt n6 During the quarter, the following companies have been incorporated: n - Auro Cure Private Limited was incorporated as a wholly owned subsidiary of Aurobindo Pharma Ltd w.e.f. 5 July 2020 n - Auro Zest Private Limited was incorporated as a wholly owned subsidiary of Aurobindo Pharma Ltd w.e.f. 6 August 2020 n - Aurobindo Pharma Foundation was incorporated as a wholly owned subsidiary of Aurobindo Pharma Ltd under Section 8 of the Companies Act 2013 w.e.f. 20 July 2020. nand Aurovitas Pharma Ceska Republica s.r.o a wholly owned stepdown subsidiary of Agile Pharma B.V. merged with Aurovitas Spol s.r.o (Formerly Apotex (CR) Spol s.r.o.) w.e.f. 1 April, 2020 n ttttttt n7 Foreign exchange gain/loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs. n ttttttt n8 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Parent Company has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates. Single segment 2020-04-01 2020-09-30 Unaudited Consolidated 124082200000.00 1693400000.00 125775600000.00 43233400000.00 12762100000.00 -6764300000.00 17998900000.00 367800000.00 5128600000.00 29950500000.00 102677000000.00 23098600000.00 0.00 23098600000.00 7929800000.00 -1019800000.00 6910000000.00 0.00 16188600000.00 0.00 0.00 0.00 -325300000.00 15863300000.00 178100000.00 16041400000.00 15868100000.00 -4800000.00 16046200000.00 -4800000.00 585900000.00 1 27.08 27.08 0.00 0.00 27.08 27.08 Other Expenses 16230100000.00 Other Expenses 29950500000.00 308800000.00 -11359700000.00 4936500000.00 0.00 -1053100000.00 -1300000.00 0.00 230800000.00 0.00 3340900000.00 0.00 1062800000.00 0.00 5128600000.00 1287400000.00 -718300000.00 0.00 0.00 35900000.00 -204800000.00 0.00 93100000.00 0.00 -68900000.00 0.00 0.00 0.00 118600000.00 0.00 2951100000.00 26049700000.00 0.00 0.00 0.00 4648400000.00 0.00 21401300000.00 0.00 0.00 0.00 1678900000.00 0.00 0.00 0.00 0.00 0.00 5484400000.00 0.00 0.00 0.00 0.00 0.00 0.00 228600000.00 1065500000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 92200000.00 0.00 -313400000.00 0.00 -8221400000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 257400000.00 5568200000.00 0.00 681000000.00 732100000.00 222700000.00 0.00 0.00 -6946600000.00 6233300000.00 -54000000.00 6179300000.00 27468200000.00 33647500000.00